Temasek Trust's C3H Leads $1.2M Funding for Singaporean Healthtech Firm Injewelme

Temasek Trust's C3H Leads $1.2M Funding for Singaporean Healthtech Firm Injewelme

Eco-Business
Eco-BusinessApr 9, 2026

Why It Matters

The funding fast‑tracks a scalable, AI‑driven health monitoring tool that addresses rising climate‑induced health risks, creating new revenue streams for insurers and providers while enhancing public health resilience.

Key Takeaways

  • C3H leads $1.2M round for injewelme.
  • DHV tech measures 20+ vitals via camera in 30 seconds.
  • AI model achieves 95% detection accuracy in pilots.
  • Funding targets Singapore rollout and SE Asia expansion.
  • Partnerships open access to Temasek ecosystem and insurers.

Pulse Analysis

Climate‑related heat stress is emerging as a silent driver of chronic disease, prompting health systems to seek real‑time, non‑invasive monitoring solutions. Injewelme’s DeepHealthVision leverages remote photoplethysmography—a camera‑based optical method—to extract heart rate, blood pressure, oxygen saturation and other biomarkers without physical contact. Coupled with in‑house predictive AI, the platform can flag physiological stress within seconds, offering clinicians a proactive window to intervene before heat exposure translates into medical emergencies. This technology aligns with a broader shift toward digital health tools that blend convenience with clinical rigor.

The US$1.2 million injection from Temasek Trust’s C3H and the Richardson Family family office does more than provide runway; it signals confidence in a model that merges climate resilience with preventive care. C3H’s involvement brings access to Temasek’s extensive network of hospitals, insurers and government agencies, accelerating customer acquisition in Singapore’s tightly regulated market. By earmarking funds for Southeast Asian expansion, injewelme can tap into regions where heat stress is intensifying and where mobile‑first health solutions are rapidly gaining acceptance. The partnership also offers strategic guidance on data governance, a critical factor for AI‑driven health products.

Beyond immediate commercial gains, injewelme’s approach could reshape how insurers price risk and how employers safeguard workforce safety. Continuous, camera‑based health snapshots enable granular risk profiling, supporting dynamic insurance premiums and targeted wellness programs. In elder‑care settings, the technology promises unobtrusive monitoring, reducing the need for frequent clinic visits. As climate variability accelerates, scalable, AI‑enabled health platforms like DHV will become essential components of national health strategies, positioning injewelme at the nexus of technology, sustainability and public health.

Temasek Trust's C3H leads $1.2M funding for Singaporean healthtech firm injewelme

Comments

Want to join the conversation?

Loading comments...